Entyvio, the brand name for the generic vedolizumab, is a monoclonal antibody that is either injected or infused into patients who suffer from severe forms of the inflammatory bowel diseases ulcerative colitis (UC) or Crohn’s disease and have not responded to other therapies. In this article, we will explore what Entyvio is, its potential side effects and limitations, and some holistic alternatives and lifestyle changes that may help relieve symptoms instead of, or in addition to, Entyvio.
What Is Entyvio and What Does It Do?
Entyvio (vedolizumab) is a drug administered via infusion to patients with moderate to severe ulcerative colitis (UC) and Crohn’s disease who have not responded to other methods of treatment, such as corticosteroids and tumor necrosis factor antagonists (anti-TNF drugs). If your Crohn's or UC has relapsed, or you're intolerant to other treatments, your health care provider may suggest that you consider Entyvio.
Entyvio is a biologic, a drug made from biological materials, such as proteins or DNA. Biologics target specific parts of the immune system in order to fight disease. How vedolizumab works is not entirely understood, but it is thought to block T-cells (white blood cells that help the immune system battle germs) and components of the innate, or nonspecific, immune response from attacking the intestines and causing inflammation. (Source, Source)
In addition to being a biologic, vedolizumab also belongs to a class of medicines known as integrin receptor antagonists, also called anti-integrin therapy. These drugs block the action of certain cells in the body that specifically cause inflammation. Entyvio is not associated with the occurrence of dangerous side effects, so it's considered to be safer for older patients, as well as for patients with multiple sclerosis. (Source)
How Is Entyvio Administered?
Entyvio is administered intravenously (IV) or as an injection (although so far the injectable version hasn't been approved in the United States). The infusion takes about 30 minutes, although you might spend a couple of hours at the clinic, since a health care provider will monitor you both throughout the process and afterward to check for side effects and adverse reactions. (Source, Source)
How Long Do You Stay on Entyvio?
When you first start Entyvio, you’ll begin with 3 infusions. Your first dose will be considered week 0, your second at week 2, and then the third at week 6. After those initial doses, you'll be given maintenance doses every 8 weeks.
Some patients may feel a benefit within 2 to 3 weeks of starting therapy, but it typically takes 6 to 8 weeks in ulcerative colitis and 10 to 14 weeks in Crohn’s disease to achieve a significant benefit. If you’re not showing improvement in your symptoms by week 14, your health care provider may choose another course of treatment.
Once you've been on Entyvio for a year, you'll receive 6 doses every year. (Source)
Contraindications and Cautions for Entyvio Use
You should alert your health care provider before starting Entyvio if you:
- are pregnant or planning to become pregnant: It's not yet known if Entyvio is safe to take during pregnancy.
- are breastfeeding or planning to breastfeed, since Entyvio can pass into breast milk
- have an allergy to Entyvio or anything in it
- have liver problems
- have tuberculosis or have been in close contact with someone who does
- have signs of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores, tiredness, or pain during urination
- have recently gotten a vaccine or are scheduled to get one
- are taking any other medications, especially a tumor necrosis factor (TNF) blocker, a corticosteroid, or any medication that suppresses your immune system
- are taking vitamins or supplements, such as probiotics
Side Effects of Entyvio
Common side effects of Entyvio may include:
- injection site reactions such as redness, itching, bruising, pain, and swelling
- infections such as cold, flu, sinusitis, and bronchitis
- nausea
- headaches
- pain in the throat, arms, legs, and joints
- signs of infection such as chills and fever
- fatigue
(Source)
More serious side effects of vedolizumab are rare, but possible. They include:
- allergic reactions related to the infusion: A health care provider will monitor you during the infusion and for some time afterward, watching for signs of a reaction, such as swelling of the lips, tongue, throat, or face, itching, a rash, shortness of breath, trouble breathing, wheezing, dizziness, feeling hot, or heart palpitations.
- serious infections: Reported vedolizumab-related infections include tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. Your health care provider should test you for tuberculosis before you begin taking Entyvio.
- progressive multifocal leukoencephalopathy (PML): The risk of developing this rare brain infection while taking vedolizumab is small.
- pancreatitis
- reactivation of hepatitis B
- liver damage
(Source, Source, Source,Source)
New Symptoms Requiring Medical Attention
If you experience any of the following while on vedolizumab, contact your health care provider:
- confusion
- problems thinking
- loss of balance
- change in the way you walk or talk
- decreased strength or weakness on one side of the body
- blurred vision or loss of vision
- fatigue
- loss of appetite
- pain in the abdomen on your right side
- jaundice, or yellowing of the skin and eyes
- dark urine
(Source)
Limitations of Entyvio
While Entyvio has shown efficacy in inducing and maintaining remission in patients with inflammatory bowel disease (IBD), it also has its limitations. For example, because vedolizumab does not suppress immune response, it was thought it would not pose the same risk of serious infections that immunosuppressant drugs do. However, a recent study suggests this may not be the case.
A large review of IBD patients in the United States and France found that overall the risk of serious infections did not differ between patients on vedolizumab and those being treated with immunosuppressants known as TNF inhibitors. However, the study found that vedolizumab was less likely than TNF inhibitors to cause serious infections in those with UC. (Source)
Furthermore, vedolizumab may not be effective for all patients with IBD, as some patients may develop antibodies against the medication, reducing its effectiveness. Overall, while vedolizumab has shown promise in treating Crohn’s and UC, it is not without limitations and careful consideration should be given to its use in individual patients.